TY - JOUR
T1 - Special Considerations in the Care of Women With Advanced Heart Failure
AU - Ebong, Imo A.
AU - DeFilippis, Ersilia M.
AU - Hamad, Eman A.
AU - Hsich, Eileen M.
AU - Randhawa, Varinder K.
AU - Billia, Filio
AU - Kassi, Mahwash
AU - Bhardwaj, Anju
AU - Byku, Mirnela
AU - Munagala, Mrudala R.
AU - Rao, Roopa A.
AU - Hackmann, Amy E.
AU - Gidea, Claudia G.
AU - DeMarco, Teresa
AU - Hall, Shelley A.
N1 - Funding Information:
The authors thank the members of the Women in Heart Transplant and Mechanical Circulatory Support Group for their valuable insights and contributions.
Publisher Copyright:
Copyright © 2022 Ebong, DeFilippis, Hamad, Hsich, Randhawa, Billia, Kassi, Bhardwaj, Byku, Munagala, Rao, Hackmann, Gidea, DeMarco and Hall.
PY - 2022/7/11
Y1 - 2022/7/11
N2 - Advanced heart failure (AHF) is associated with increased morbidity and mortality, and greater healthcare utilization. Recognition requires a thorough clinical assessment and appropriate risk stratification. There are persisting inequities in the allocation of AHF therapies. Women are less likely to be referred for evaluation of candidacy for heart transplantation or left ventricular assist device despite facing a higher risk of AHF-related mortality. Sex-specific risk factors influence progression to advanced disease and should be considered when evaluating women for advanced therapies. The purpose of this review is to discuss the role of sex hormones on the pathophysiology of AHF, describe the clinical presentation, diagnostic evaluation and definitive therapies of AHF in women with special attention to pregnancy, lactation, contraception and menopause. Future studies are needed to address areas of equipoise in the care of women with AHF.
AB - Advanced heart failure (AHF) is associated with increased morbidity and mortality, and greater healthcare utilization. Recognition requires a thorough clinical assessment and appropriate risk stratification. There are persisting inequities in the allocation of AHF therapies. Women are less likely to be referred for evaluation of candidacy for heart transplantation or left ventricular assist device despite facing a higher risk of AHF-related mortality. Sex-specific risk factors influence progression to advanced disease and should be considered when evaluating women for advanced therapies. The purpose of this review is to discuss the role of sex hormones on the pathophysiology of AHF, describe the clinical presentation, diagnostic evaluation and definitive therapies of AHF in women with special attention to pregnancy, lactation, contraception and menopause. Future studies are needed to address areas of equipoise in the care of women with AHF.
KW - advanced heart failure
KW - advanced therapies (ATs)
KW - heart transplant
KW - ventricular assist device
KW - women
UR - http://www.scopus.com/inward/record.url?scp=85134637432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134637432&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2022.890108
DO - 10.3389/fcvm.2022.890108
M3 - Review article
AN - SCOPUS:85134637432
VL - 9
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
SN - 2297-055X
M1 - 890108
ER -